Enterprise Value
-103.5M
Cash
247.6M
Avg Qtr Burn
-23.12M
Short % of Float
11.80%
Insider Ownership
1.60%
Institutional Own.
92.16%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ADI-270 Details Cancer, Solid tumor/s, Hematologic malignancies | Phase 1 Data readout | |
ADI-001 (allogeneic CAR gamma-delta T cell therapy) Details Lupus nephritis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 1 Data readout | |
ADI-001 (allogeneic CAR gamma-delta T cell therapy) Details Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma | Phase 1 Data readout |